Lycia Therapeutics (NASDAQ:LYCA) Major Shareholder Purchases $26,330.00 in Stock

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par purchased 1,000 shares of the business’s stock in a transaction dated Thursday, October 29th. The shares were purchased at an average cost of $26.33 per share, for a total transaction of $26,330.00. Following the completion of the purchase, the insider directly owned 6,841,233 shares of the company’s stock, valued at approximately $180,129,664.89. This represents a 0.01% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, October 30th, Venrock Healthcare Capital Par purchased 9,004 shares of Lycia Therapeutics stock. The shares were purchased at an average price of $26.28 per share, for a total transaction of $236,625.12.
• On Wednesday, October 28th, Venrock Healthcare Capital Par acquired 15,000 shares of Lycia Therapeutics stock. The stock was purchased at an average cost of $25.45 per share, with a total value of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par acquired 39,796 shares of Lycia Therapeutics stock. The stock was purchased at an average cost of $26.62 per share, with a total value of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par acquired 1,952,705 shares of Lycia Therapeutics stock. The stock was acquired at an average price of $18.04 per share, with a total value of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The shares were acquired at an average price of $25.91 per share, for a total transaction of $1,371,649.49.

Lycia Therapeutics Stock Performance

NASDAQ LYCA traded down $1.33 on Friday, hitting $26.40. The company’s stock had a trading volume of 202,428 shares, compared to its average volume of 857,210. Lycia Therapeutics, Inc. has a 1-year low of $22.19 and a 1-year high of $36.49.

About Lycia Therapeutics

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.